<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109390</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-014</org_study_id>
    <nct_id>NCT05109390</nct_id>
  </id_info>
  <brief_title>A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults</brief_title>
  <official_title>A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in&#xD;
      healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2018</start_date>
  <completion_date type="Actual">October 17, 2018</completion_date>
  <primary_completion_date type="Actual">October 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This was a 3-part study, each part is a fixed-sequence with 2 periods.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Cyclosporine Maximum Observed Concentration (Cmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Cyclosporine Time To Reach The Maximum Observed Concentration (Tmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Cyclosporine Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tacrolimus Cmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tacrolimus Tmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tacrolimus AUC0-inf Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Omeprazole Cmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Omeprazole Tmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Omeprazole Area Under The Concentration-time Curve From Time 0 To The 24-hour Time Point (AUC0-24) Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Multiple-dose Omeprazole</measure>
    <time_frame>Up to 8 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Multiple-dose Omeprazole</measure>
    <time_frame>Up to 8 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Danicopan Area Under The Concentration-time Curve From Time 0 To The 8-hour Time Point (AUC0-8) Alone Versus In The Presence Of Multiple-dose Omeprazole</measure>
    <time_frame>Up to 8 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/Simethicone</measure>
    <time_frame>Up to 8 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/Simethicone</measure>
    <time_frame>Up to 8 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Steady-state Danicopan AUC0-8 Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/Simethicone</measure>
    <time_frame>Up to 8 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants Experiencing Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 through up to Day 31</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Danicopan plus Cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (N=14) received danicopan and cyclosporine in a fixed sequence over 2 periods:&#xD;
Treatment A (Period 1): 300 milligrams (mg) cyclosporine administered on Day 1.&#xD;
Treatment B (Period 2): 200 mg danicopan administered 3 times daily (TID) on Days 1-7 with 300 mg cyclosporine coadministered on Day 5.&#xD;
There was a washout period of 3 days between the dose of cyclosporine in Period 1 and the first dose of danicopan in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Danicopan plus Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (N=28) received danicopan and tacrolimus in a fixed sequence over 2 periods:&#xD;
Treatment C (Period 1): 2 mg tacrolimus administered on Day 1.&#xD;
Treatment D (Period 2): 200 mg danicopan administered TID on Days 1-10 with 2 mg tacrolimus coadministered on Day 5.&#xD;
There was a washout period of 7 days between the dose of tacrolimus in Period 1 and the first dose of danicopan in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Danicopan plus Antacids and Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (N=30) received danicopan, calcium carbonate, aluminum/magnesium hydroxide/simethicone, and omeprazole in fixed sequences over 2 periods:&#xD;
Treatment E1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment E2 (Period 1): 200 mg danicopan coadministered with 1 gram calcium carbonate on Day 5.&#xD;
Treatment F1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment F2 (Period 1): 200 mg danicopan coadministered with 200 mg aluminum hydroxide/200 magnesium hydroxide/25 mg simethicone on Day 5.&#xD;
Note: Participants were randomized in a 1:1 ratio to receive either Treatment E2 or F2 coadministered with danicopan on Day 5.&#xD;
Treatment G1 (Period 2): 40 mg omeprazole administered once daily (QD) on Days 1-4.&#xD;
Treatment G2 (Period 2): 40 mg omeprazole administered QD with 200 mg danicopan administered orally TID on Days 5-8.&#xD;
There was a washout period of 2 days between the last dose of danicopan in Period 1 and the first dose of omeprazole in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 1: Danicopan plus Cyclosporine</arm_group_label>
    <arm_group_label>Part 2: Danicopan plus Tacrolimus</arm_group_label>
    <arm_group_label>Part 3: Danicopan plus Antacids and Omeprazole</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Oral capsule.</description>
    <arm_group_label>Part 1: Danicopan plus Cyclosporine</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Oral capsule.</description>
    <arm_group_label>Part 2: Danicopan plus Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Chewable tablet.</description>
    <arm_group_label>Part 3: Danicopan plus Antacids and Omeprazole</arm_group_label>
    <other_name>Antacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aluminum/Magnesium Hydroxide/Simethicone</intervention_name>
    <description>Chewable tablet.</description>
    <arm_group_label>Part 3: Danicopan plus Antacids and Omeprazole</arm_group_label>
    <other_name>Antacid</other_name>
    <other_name>Gelusil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Oral, delayed-release capsule.</description>
    <arm_group_label>Part 3: Danicopan plus Antacids and Omeprazole</arm_group_label>
    <other_name>Prilosec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at Screening.&#xD;
&#xD;
          -  Female participants must have been of non-childbearing potential and not needing to&#xD;
             employ a method of contraception.&#xD;
&#xD;
          -  Non-sterile male participants must have agreed to abstinence or used a highly&#xD;
             effective method of contraception.&#xD;
&#xD;
          -  No clinically significant history or presence of electrocardiogram findings at&#xD;
             Screening and Day -1 of Period 1.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of any clinically significant deviation from normal in clinical laboratory&#xD;
             evaluations.&#xD;
&#xD;
          -  History of any medical or psychiatric condition or disease that might have limited the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse within 2 years prior to first dosing;&#xD;
             current tobacco/nicotine users and smokers; positive drugs-of-abuse and/or alcohol&#xD;
             screen at Screening or Day -1 of Period 1.&#xD;
&#xD;
          -  Any previous procedure that could have altered absorption or excretion of orally&#xD;
             administered drugs.&#xD;
&#xD;
          -  A history of significant multiple and/or severe allergies or had had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          -  Body temperature ≥ 38°Celsius at Screening, on Day -1, or Day 1 prior to first dosing;&#xD;
             history of febrile illness, or other evidence of infection, within 14 days prior to&#xD;
             first dosing.&#xD;
&#xD;
          -  Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             first dosing, whichever was longer.&#xD;
&#xD;
          -  Donation of whole blood from 3 months prior to first dosing, or of plasma from 30 days&#xD;
             before first dosing; receipt of blood products within 6 months prior to first dosing.&#xD;
&#xD;
          -  Part 3 Only: Genotyped as poor metabolizer of cytochrome P450 2C19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Drug Interaction</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Antacids</keyword>
  <keyword>Omeprazole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, drug combination</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

